Table 1.
Demographic data of the COPD patients (n = 443)
| Age <75 years | Age ≥75 years | p value | |
|---|---|---|---|
| No. of subjects | 252 | 191 | |
| Age (mean, years) | 66.9 | 80.0 | |
| Sex (male/female) | 231/21 | 175/16 | n.s. |
| Smoking amount (mean, pack-year) | 56.9 | 55.6 | n.s. |
| Current smoker (%) | 17.3 | 7.7 | 0.004 |
| BMI (mean, kg/m2) | 22.5 | 22.3 | n.s. |
| VC (mean, ml) | 3365 | 2934 | <0.001 |
| VC (mean, % predicted) | 93.8 | 93.5 | n.s. |
| FEV1 (mean, ml) | 1717 | 1465 | <0.001 |
| FEV1 (mean, % predicted) | 60.5 | 62.1 | n.s. |
| GOLD grade (I/II/III/IV) | 52/114/67/19 | 41/88/48/14 | n.s. |
| LTOT (%) | 10.7 | 15.9 | n.s. |
| CAT (mean) | 12.5 | 12.7 | n.s. |
| SGRQ symptom (mean) | 36.5 | 37.9 | n.s. |
| SGRQ activity (mean) | 39.7 | 47.5 | 0.001 |
| SGRQ impact (mean) | 18.3 | 22.3 | 0.04 |
| SGRQ total (mean) | 27.4 | 32.2 | 0.02 |
| Oral corticosteroids (%) | 3.2 | 3.6 | n.s. |
| Inhaled corticosteroids (%) | 35.0 | 32.8 | n.s. |
| Long-acting β2 agonists (%) | 42.0 | 48.8 | n.s. |
| Long-acting muscarinic antagonists (%) | 64.0 | 58.3 | n.s. |
BMI body mass index, VC vital capacity, FEV 1 forced expiratory volume in 1 s, GOLD Global Initiative for Obstructive Lung Disease, LTOT long-term oxygen therapy, CAT COPD assessment test, SGRQ St George’s Respiratory Questionnaire, n.s. not significant